Alantra advises Pharmamar in the sale of its two non-core business activities: Zelnova & Copyr

July 18, 2019

Madrid – Alantra, an independent global investment banking and asset management firm, has advised PharmaMar, a world leader company in the discovery of antitumor drugs of marine origin, on the sale of its 2 non-core business activities: Zelnova Zelita SA & Copyr SpA.

PharmaMar is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor properties. The firm seeks innovative products to provide healthcare professionals with new tools to treat cancer. PharmaMar is quoted on the Spanish Stock Market and is looking to be listed on The Nasdaq Stock Market.

The company decided to divest its non-core business activities and engaged Alantra to sell:

Zelnova, a non-food consumer goods company that develops and markets (B2B & B2C) cleaning, hygiene and pest control products for the domestic, industrial and hospitality sectors. It is a leader in several segments of the European insecticide market with a strong portfolio of brands for both household and professional use.

Copyr, the pyrethrum company, focuses on pyrethrum and pyrethroids products for professional and amateur use in the agricultural, pest control, industrial and HoReCa (foodservice) segments.

The transaction highlights Alantra’s expertise advising on sell-side processes, managing both strategic and financial interested investors and achieving the best transaction in terms of price and structure for its client.

By Yago Sánchez July 18, 2019 Corporate News, Press Releases

Related Posts